A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

STATUS

Recruiting
End date

Mar 1, 2024
participants needed

177
sponsor

Micro Medical Solution, Inc.

Send

Updated on 21 April 2022

See if I qualify

arteriopathy

stenosis

ischemia

vascular disease

limb ischemia

critical limb ischaemia

Summary

Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.

Details

Condition	Peripheral Arterial Disease
Treatment	standard PTA, MicroStent and Standard PTA
Clinical Study Identifier	NCT03477604
Sponsor	Micro Medical Solution, Inc.
Last Modified on	21 April 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Subject is a male or a non-pregnant female adult between the age of 21 and 90 years old
	Subject has documented clinical evidence of critical limb ischemia (CLI) in the target limb prior to the index procedure, with a Rutherford Classification score of 4-5
	The subject, or subject's designated legal representative, has been informed of the nature of the study and is willing to provide written informed consent
	Subject is willing to comply with all required follow-up visits
	Subject life expectancy is ≥1 year per the Principal Investigator
	Angiographic Inclusion Criteria
	Target vessel reconstitutes at or above the ankle with inline flow to at least one patent (<50% stenosis) inframalleolar outflow vessel
	Subject has a lesion, with ≥ 70% stenosis and ≤ 12.0 cm in length located at or distal to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior tibial, posterior tibial or peroneal arteries
	Target lesion has a reference vessel diameter of 2.5 - 4.5 mm
	The target lesion is able to be crossed with a guidewire to facilitate treatment with the randomized device
Exclusion Criteria
	Subject has a wound/ulcer on the forefoot with a surface area >4cm² or osteomyelitis involving the calcaneus bone
	Subject had a prior or has a planned index limb amputation above the ankle
	Subject is pregnant, plans to become pregnant, or is nursing
	Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound visualization (e.g. body habitus)
	Subject has a history of hypercoagulation/clotting disorders or acute thrombosis
	Subject has allergy to iodinated contrast media that cannot be adequately managed with medication
	Subject is in acute renal failure
	Subject has an active systemic infection
	Subject is participating in another research study involving an investigational device, biologic, or drug that has not completed the primary endpoint at the time of randomization/enrollment
	Subject has other comorbidities that - in the opinion of the investigator - preclude them from receiving study treatment and/or from completing the required study follow-up assessments
	Subject presents with acute limb ischemia or acute thrombosis of the target limb
	Failure to successfully treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g embolism)
	Subject has experienced myocardial infarction, thrombolysis, or angina less than 30 days prior to the index procedure
	Failure to successfully treat significant non-target infra-popliteal lesions. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g. embolism)
	Subject had a stroke within 3 months of index procedure
	Target lesion is within a previously placed stent
	Angiographic exclusion criteria

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

critical limb ischaemia

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)